Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 15/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830288 | 0.82 | GRM2 (0.51) | GRM2ALDH1A1NPSR1KDM4EMAPK1 | |
| SCHEMBL169741 | 0.81 | GRM2 (0.64) | GRM2 | |
| SCHEMBL4131086 | 0.81 | GRM2 (0.42) | GRM2ALDH1A1KDM4EMAPK1 | |
| SCHEMBL1828147 | 0.79 | LMNA (0.61) | GRM2LMNA | |
| SCHEMBL11211380 | 0.78 | TYR (0.50) | GRM2ALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL1827879 | 0.77 | GRM2 (0.59) | GRM2 | |
| SCHEMBL1039006 | 0.76 | ALDH1A1 (0.55) | GRM2ALDH1A1NPSR1MEN1LMNA | |
| SCHEMBL8154381 | 0.76 | ALDH1A1 (0.55) | GRM2ALDH1A1NPSR1LMNAHTT | |
| SCHEMBL259368 | 0.75 | MAPT (0.59) | GRM2ALDH1A1KDM4EMAPK1MEN1 | |
| SCHEMBL171733 | 0.73 | GRM2 (0.46) | GRM2ALDH1A1KDM4EMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426125-B1 | 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906939-B2 | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives | Janssen Pharmaceuticals, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8796311-B2 | — | — | 2014-08-05 | — | — | US | disclosed |
| US-20100063092-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2134701-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134708-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2134690-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107481-A1 | 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107479-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063092-A1 | 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES | GRM2, GRIK2, GRIN2C | GRM2 1/4885ALDH1A1 2407/4885NPSR1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.